Pro108Ser mutant of SARS-CoV-2 3CLpro reduces the enzymatic activity and ameliorates COVID-19 severity in Japan
View ORCID ProfileKodai Abe, Yasuaki Kabe, Susumu Uchiyama, View ORCID ProfileYuka W. Iwasaki, Hirotsugu Ishizu, Yoshifumi Uwamino, View ORCID ProfileToshiki Takenouchi, Shunsuke Uno, Makoto Ishii, Takahiro Maruno, Masanori Noda, Mitsuru Murata, Naoki Hasegawa, Hideyuki Saya, Yuko Kitagawa, Koichi Fukunaga, Masayuki Amagai, Haruhiko Siomi, Makoto Suematsu, Kenjiro Kosaki, Keio Donner Project
doi: https://doi.org/10.1101/2020.11.24.20235952
Kodai Abe
1Department of Surgery, Keio University School of Medicine, Tokyo, Japan
14Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan
Yasuaki Kabe
2Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
Susumu Uchiyama
3Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, Japan
4Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Japan
5Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan
Yuka W. Iwasaki
6Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan
Hirotsugu Ishizu
6Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan
Yoshifumi Uwamino
7Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
11Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
Toshiki Takenouchi
8Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
Shunsuke Uno
7Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
Makoto Ishii
9Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Takahiro Maruno
3Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, Japan
Masanori Noda
10U-Medico, Inc., Osaka, Japan
Mitsuru Murata
11Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
Naoki Hasegawa
7Division of Infection Diseases and Infection Control, Keio University Hospital, Tokyo, Japan: Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
Hideyuki Saya
12Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
Yuko Kitagawa
1Department of Surgery, Keio University School of Medicine, Tokyo, Japan
Koichi Fukunaga
9Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Masayuki Amagai
13Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
Haruhiko Siomi
6Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan
Makoto Suematsu
2Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan
Kenjiro Kosaki
14Center for Medical Genetics, Keio University School of Medicine, Tokyo, Japan
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
- Acknowledgment table[supplements/235952_file03.xlsx]
- Supplementary information[supplements/235952_file04.docx]
Posted February 02, 2021.
Pro108Ser mutant of SARS-CoV-2 3CLpro reduces the enzymatic activity and ameliorates COVID-19 severity in Japan
Kodai Abe, Yasuaki Kabe, Susumu Uchiyama, Yuka W. Iwasaki, Hirotsugu Ishizu, Yoshifumi Uwamino, Toshiki Takenouchi, Shunsuke Uno, Makoto Ishii, Takahiro Maruno, Masanori Noda, Mitsuru Murata, Naoki Hasegawa, Hideyuki Saya, Yuko Kitagawa, Koichi Fukunaga, Masayuki Amagai, Haruhiko Siomi, Makoto Suematsu, Kenjiro Kosaki, Keio Donner Project
medRxiv 2020.11.24.20235952; doi: https://doi.org/10.1101/2020.11.24.20235952
Pro108Ser mutant of SARS-CoV-2 3CLpro reduces the enzymatic activity and ameliorates COVID-19 severity in Japan
Kodai Abe, Yasuaki Kabe, Susumu Uchiyama, Yuka W. Iwasaki, Hirotsugu Ishizu, Yoshifumi Uwamino, Toshiki Takenouchi, Shunsuke Uno, Makoto Ishii, Takahiro Maruno, Masanori Noda, Mitsuru Murata, Naoki Hasegawa, Hideyuki Saya, Yuko Kitagawa, Koichi Fukunaga, Masayuki Amagai, Haruhiko Siomi, Makoto Suematsu, Kenjiro Kosaki, Keio Donner Project
medRxiv 2020.11.24.20235952; doi: https://doi.org/10.1101/2020.11.24.20235952
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2656)
- Dermatology (224)
- Emergency Medicine (400)
- Epidemiology (12248)
- Forensic Medicine (10)
- Gastroenterology (763)
- Genetic and Genomic Medicine (4114)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2666)
- Health Policy (1005)
- Hematology (364)
- HIV/AIDS (853)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (439)
- Neurology (3897)
- Nursing (210)
- Nutrition (578)
- Oncology (2037)
- Ophthalmology (586)
- Orthopedics (241)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6538)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (451)
- Toxicology (53)
- Transplantation (185)
- Urology (166)